Last reviewed · How we verify
CGRP mAbs and onabotulinumtoxin A
This combination blocks calcitonin gene-related peptide (CGRP) signaling via monoclonal antibodies while simultaneously inhibiting acetylcholine release at the neuromuscular junction via onabotulinumtoxin A to reduce migraine frequency and severity.
This combination blocks calcitonin gene-related peptide (CGRP) signaling via monoclonal antibodies while simultaneously inhibiting acetylcholine release at the neuromuscular junction via onabotulinumtoxin A to reduce migraine frequency and severity. Used for Chronic migraine (phase 3 combination study).
At a glance
| Generic name | CGRP mAbs and onabotulinumtoxin A |
|---|---|
| Sponsor | Oslo University Hospital |
| Drug class | Monoclonal antibody + neurotoxin combination |
| Target | CGRP/CGRP receptor and acetylcholine (via SNARE complex inhibition) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
CGRP mAbs bind to CGRP or its receptor to prevent neuropeptide-mediated vasodilation and neurogenic inflammation implicated in migraine pathogenesis. OnabotulinumtoxinA blocks acetylcholine release at motor endplates, reducing muscle tension and potentially modulating pain signaling in chronic migraine. The combination targets complementary pathways in migraine biology.
Approved indications
- Chronic migraine (phase 3 combination study)
Common side effects
- Injection site reactions
- Muscle weakness
- Headache
- Neck pain
- Antibody formation (CGRP mAbs)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |